Patent 11179470 was granted and assigned to ProLynx on November, 2021 by the United States Patent and Trademark Office.
Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.